BenefitsPRO.com

BenefitsPRO.com is an online destination for benefits professionals, providing news, resources, and tools. The site covers the complex and ever-changing benefits market with established resources and news reporting capabilities combined with proprietary market data and relevant content from across the web. BenefitsPRO.com aims to help professionals adapt to new ways of thriving in a disrupted environment by translating the impact of regulations and technology into digestible, shareable information. The site also offers sales and prospecting tools for benefits professionals to differentiate and grow their practices.

95%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site is known for its high journalistic standards. It strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. It has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

85%

Examples:

  • GLP-1 drugs like Wegovy do not currently include labeling that directly warns people about the potential risk of gastroparesis.
  • New research links the use of Ozempic, Wegovy, and other GLP-1 drugs to a greater risk of gastroparesis.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

  • GLP-1 Agonists and Gastroparesis: Uncovering the Connection and Its Implications

    GLP-1 Agonists and Gastroparesis: Uncovering the Connection and Its Implications

    Broke On: Monday, 20 May 2024 Weight loss drugs, such as GLP-1 agonists like Ozempic and Wegovy, have been linked to an increased risk of gastroparesis. Studies suggest that 10 out of every 10,000 people taking these medications for weight loss are diagnosed with gastroparesis at least six months later compared to 4 out of every 10,000 people not taking the medication. Over fifty lawsuits have been filed against drug manufacturers due to potential side effects and lack of clear warnings about this risk.